Research & Development


Uterine fibroids (myoma) are the most common benign, solid tumours of the female genital tract in women of reproductive age, affecting over 40 million women of reproductive age in Europe and USA. Cardinal symptoms:

  • Heavy menstrual bleeding and anemia
  • Abdominal pain and pressure
  • Increased urinary frequency
  • Infertility

It is a leading cause of hysterectomy.

(Ulipristal Acetate / PGL4001)
European Marketing Authorization received in February 2012


Endometriosis is a benign gynaecological disease characterised by the presence of functional endometrial tissue fragments growing outside the uterus cavity, most frequently on the peritoneum, the ovaries, and the bowel. Endometriosis affects over 20 million women of reproductive age (EU & USA) with 5 million suffering from chronic pelvic pain.

Main symptoms:

  • Chronic pelvic pain
  • Painful menstruations
  • Dyspareunia (painful sexual intercourse)
  • Infertility

(Steroid Sulfatase Inhibitor, STS-I)
Phase IIa

(c-Jun-N-Terminal Kinase Inhibitor (JNK-I), Bentamapimod)
Phase IIa


Infertility is a condition described as the failure to conceive after regular unprotected intercourse during at least one year for couples below 35 years and during 6 months for couples above 35 years. It affects 10 million couples in the EU, 6 million in the USA and 80 million worldwide.

(Somatostatin Antagonist, SST-ATG)
Ovarian Reserve Modulation: Pre-Clinical Development


Adhesion formation is a common outcome of surgery, occurring in 90-95% of patients. Approximately 4 million pelvic and abdominal surgery procedures are performed each year in the EU, and a similar number in the US. There can be an adhesion between organs in the pelvis, bowel to bowel, bowel to uterus, bowel to the ovary, or to the abdominal wall. At their most extreme, they can result in infertility, pain and bowel obstructions. Endometriosis and Endometriosis-related pelvic surgery are leading causes of abdominal adhesions.

(c-Jun-N-Terminal Kinase Inhibitor (JNK-I), Bentamapimod)
Phase IIa